The online version of this article (https://doi.org/10.1007/s00392-019-01432-y) contains supplementary material, which is available to authorized users.
Atrial high rate episodes (AHREs) detected by cardiac implantable electronic devices (CIEDs) are associated with an increased risk of stroke. However, the impact of AHRE on improving stroke risk stratification scheme remains uncertain.
The purpose of this study was to assess the impact of AHRE on prognosis in relation with cardiovascular events and risk stratification.
A total of 856 consecutive patients who had dual-chamber CIEDs implanted were retrospectively analyzed. To detect AHREs, they were monitored for 6 months after CIEDs’ implantation and were followed for a mean of 4.0 years for clinical outcomes such as thromboembolism or death.
Overall, 125 (14.6%) of patients developed AHREs within the first 6 months (median age 72.0 years, 39.3% female). Patients with AHREs had a high rate of thromboembolism (2.6%/year) and mortality (3.0%/year). On multivariate analysis, AHRE was significantly associated with increased risk of thromboembolism [hazard ratio (HR) 3.40; 95% confidence interval (CI) 1.38–8.37, P = 0.01] and death (HR 3.47; 95% CI 1.51–7.95; P < 0.01). The predictive abilities of the CHADS2 and CHA2DS2-VASc scores were modest, with no significant improvements by adding AHRE to those scores. However, the integrated discrimination improvement and net reclassification improvement showed that the addition of AHRE to the CHADS2 and CHA2DS2-VASc scores statistically improved their predictive ability for the composite outcome.
AHRE was an independent factor associated with increased risk of clinical outcomes. The addition of AHRE to the clinical risk scores significantly improved discrimination for thromboembolism or death.
Supplementary material 1 (DOCX 75 KB)392_2019_1432_MOESM1_ESM.docx
Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van der Harst P, Hillege HL, Van Gilst WH, Van Gelder IC, Rienstra M (2015) Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: a community-based study from the Netherlands. J Am Coll Cardiol 66:1000–1007 CrossRef
Lip GYH (2017) The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 14:627–628 CrossRef
Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH (2018) Integrated care management of patients with atrial fibrillation and risk of cardiovascular events: the ABC (atrial fibrillation better care) pathway in the ATHERO-AF study cohort. Mayo Clin Proc 1:1. https://doi.org/10.1016/j.mayocp.2018.10.022
Healey JS, Oldgren J, Ezekowitz M et al (2016) Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet 388:1161–1169 CrossRef
Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK (2009) Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 40:235–240 CrossRef
Savelieva I, Camm AJ (2000) Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 4:369–382 CrossRef
Lin HJ, Wolf PA, Benjamin EJ, Belanger AJ, D’Agostino RB (1995) Newly diagnosed atrial fibrillation and acute stroke. The Framingham Study. Stroke 26:1527–1530 CrossRef
Mairesse GH, Moran P, Van Gelder IC et al (2017) Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Europace 19:1589–1623 CrossRef
Pollak WM, Simmons JD, Interian A Jr, Atapattu SA, Castellanos A, Myerburg RJ, Mitrani RD (2001) Clinical utility of intraatrial pacemaker stored electrograms to diagnose atrial fibrillation and flutter. Pacing Clin Electrophysiol 24:424–429 CrossRef
Glotzer TV, Hellkamp AS, Zimmerman J et al (2003) Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 107:1614–1619 CrossRef
Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler PD (2009) The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2:474–480 CrossRef
Healey JS, Connolly SJ, Gold MR et al (2012) Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366:120–129 CrossRef
Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962 CrossRef
DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845 CrossRef
Pencina MJ, D’Agostino RB, D’Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157–172 (discussion 207-112) CrossRef
Miyazawa K, Pastori D, Lip GYH (2018) Quantifying time in atrial fibrillation and the need for anticoagulation. Prog Cardiovasc Dis 60:537–541 CrossRef
Freedman B, Boriani G, Glotzer TV, Healey JS, Kirchhof P, Potpara TS (2017) Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat Rev Cardiol 14:701–714 CrossRef
Mahajan R, Perera T, Elliott AD et al (2018) Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. Eur Heart J 39:1407–1415 CrossRef
Lamas GA, Lee KL, Sweeney MO et al (2002) Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med 346:1854–1862 CrossRef
Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, Lamas GA, Investigators MOST (2003) Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 107:2932–2937 CrossRef
Yannopoulos D, Lurie KG, Sakaguchi S, Milstein S, Ermis C, VanHeel L, Benditt DG (2007) Reduced atrial tachyarrhythmia susceptibility after upgrade of conventional implanted pulse generator to cardiac resynchronization therapy in patients with heart failure. J Am Coll Cardiol 50:1246–1251 CrossRef
Shanmugam N, Boerdlein A, Proff J, Ong P, Valencia O, Maier SK, Bauer WR, Paul V, Sack S (2012) Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population. Europace Feb 14:230–237 CrossRef
Botto GL, Padeletti L, Santini M et al (2009) Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 20:241–248 CrossRef
Boriani G, Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, Ricci R, Biffi M, De Santo T, Corbucci G, Lip GY, Italian ATRI (2011) Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke 42:1768–1770 CrossRef
Lopes RD, Alings M, Connolly SJ et al (2017) Rationale and design of the Apixaban for the reduction of thrombo-embolism in patients with device-detected sub-clinical atrial fibrillation (ARTESiA) trial. Am Heart J 189:137–145 CrossRef
Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P (2017) Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J 190:12–18 CrossRefPubMedCentral
- Atrial high rate episodes in patients with cardiac implantable electronic devices: implications for clinical outcomes
Gregory Y. H. Lip
- Springer Berlin Heidelberg
Clinical Research in Cardiology
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
Neu im Fachgebiet Kardiologie
e.Med Kampagnen-Visual, Mail Icon II